Gilman Law LLP is Investigating Nektar Therapeutics on Behalf of Purchasers of Nektar Therapeutics Stock
About the Nektar Therapeutics Investigation
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) common stock.
Nektar Therapeutics Details of Investigation
On March 17, 2015, Nektar reported that results from a Phase 3 BEACON study of its experimental breast cancer drug, NKTR-102, failed to achieve the primary endpoint of overall survival. Further, the study failed to achieve statistical significance in the secondary endpoints of objective response rate (ORR) and progression-free survival (PFS).
Legal Help for Nektar Therapeutics Investors
If you purchased or otherwise acquired shares of Nektar Therapeutics, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.
About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.
For a free evaluation of your case or to obtain additional information, please CALL TOLL FREE (888) 252-0048.